Prognosis and Pathology of Screen-Detected Carcinomas
|
|
- Gwendolyn Carr
- 6 years ago
- Views:
Transcription
1 Prognosis and Pathology of Screen-Detected Carcinomas How Different Are They? Iris D. Nagtegaal, MD, PhD 1 ; Prue C. Allgood, PhD 3 ; Stephen W. Duffy, MSc 3 ; Olive Kearins 2 ; E. O. Sullivan, BSc 2 ; Nancy Tappenden, MPH 2 ; Matthew Wallis, MB, ChB, FRCR 4 ; and Gill Lawrence, PhD 2 BACKGROUND: It has been observed that screen-detected breast cancers have a better prognosis than symptomatic tumors, even after taking pathological tumor attributes into account. This has led to the hypothesis that screendetected tumors are substantially biologically different from symptomatic cancers. METHODS: The pathology and survival by detection mode was investigated in 21,382 breast cancers diagnosed in women aged years in the West Midlands, United Kingdom, between 1988 and Tumor attributes were compared using chi-square tests and logistic regression. Survival was analyzed using Cox regression. RESULTS: Screen-detected cancers were significantly smaller, better differentiated, and less likely to be node-positive than symptomatic cancers (P <.001 in all cases). In addition, a higher proportion of screen-detected cancers were hormone receptor-positive, and a higher proportion were tubular carcinomas (P <.001). Survival was substantially better in screen-detected breast cancers (86% at 10 yearsvs 70% for interval cancers and 58% for cancers in women unexposed to screening). Adjustment for age, tumor size, nodal status, grade, histological type, and year of diagnosis accounted for 64% (interval cancers) and 68% (unexposed women) of these survival differences, respectively. Overall survival improved with time. Approximately half of this improvement was due to the increase over time in the proportion of tumors that were screendetected. CONCLUSION: The majority of the difference in prognosis between screen-detected and symptomatic breast cancers is due to the differences in routinely measured pathological features (size, type, grade, and nodal status), leaving a small residual difference to be accounted for by other biological differences. Cancer 2011;117: VC 2010 American Cancer Society. KEYWORDS: breast cancer, prognosis, pathology, screen-detected, survival. The introduction of population-wide breast cancer screening programs has been accompanied by a decrease in breast cancer-related mortality 1,2 and by an increase in the incidence of breast cancer, notably of early-stage tumors. 3 It has been suggested that the latter may constitute overdiagnosis (ie, the detection of tumors that would not have caused problems during the lifetime of the affected women) or possibly the less extreme phenomenon of length bias, whereby slow-growing tumors have a longer window of opportunity for screen detection and are therefore overrepresented in screen-detected cancers. 4,5 Both hypotheses are consistent with biological differences between screen-detected and symptomatic cancers. 5,6 It is clear that for breast screening to work, it must detect cancers at an earlier stage. 7 Several reports indicate that breast cancers detected by screening have more favorable pathological features compared with symptomatic breast cancers, some of which may be due to a stage shift, and some to underlying biological differences In addition to stage shift and length bias or overdiagnosis, there is an artificial increase in survival due to lead time (if screening detects a tumor on average 3 years earlier than symptoms would have arisen, 3 years are added to the survival time regardless of the eventual outcome). Between screening rounds, breast cancers occur symptomatically in women with a previous negative screen. These tumors, usually called interval cancers, have a worse prognosis than screen-detected carcinomas, although it is sometimes better than that of subjects unexposed to screening. 11,12 They are likely to constitute a mixture of aggressive tumors that Corresponding author: Prue C. Allgood, PhD, CR-UK Centre for EMS, Wolfson Institute of Preventive Medicine, Charterhouse Square, London EC1M 6BQ, United Kingdom; Fax: (011) ; p.allgood@qmul.ac.uk 1 Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands; 2 West Midlands Cancer Intelligence Unit, Birmingham, United Kingdom; 3 CR-UK Center for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, London, United Kingdom; 4 Cambridge Breast Screening Unit and National Institute for Health Research, Cambridge Biomedical Research Center, Addenbrooke s Hospital Cambridge, United Kingdom We thank Rosie Day at the West Midlands Cancer Intelligence Unit for extracting the data from the cancer registration database. DOI: /cncr.25613, Received: May 20, 2010; Accepted: July 28, 2010, Published online November 2, 2010 in Wiley Online Library (wileyonlinelibrary.com) 1360 Cancer April 1, 2011
2 Breast Cancer Differences/Nagtegaal et al have developed rapidly to the symptomatic phase and less aggressive tumors that have been missed at the previous screening. In the present study, we used a database of more than 21,000 breast cancers recorded on the West Midlands Cancer Intelligence Unit s cancer registration database to address the following issues to a level of detail and precision that has not been possible in smaller tumor series: 1. What are the typical pathological features of screen-detected breast cancers and how do these differ from interval cancers and tumors in women unexposed to screening? 2. What are the implications of these differences for prognosis? 3. To what extent can the better survival of screendetected breast cancers be attributed to shifts in nodal status, tumor size, and other routinely measured histological factors, and what remains to be explained by biological and other differences? 4. What changes in tumor attributes and in survival have occurred over the period of observation, and to what extent are these changes attributable to screening or to other factors? MATERIALS AND METHODS Patients In collaboration with the National Health Service Breast Screening Programme, the West Midlands Cancer Intelligence Unit collected screening history, pathological data, and follow-up data on cancers diagnosed in women aged years in the West Midlands, United Kingdom, from 1988 to From 2002 to 2004, the dataset was expanded to include women aged years, and with an extension of the upper age limit for invitation to 70 years, nonnegligible screening was being performed in women aged years. In the present study, to avoid complications in screening history classification caused by the staggered rollout of the upper age limit extension, only data for the 21,382 breast cancers diagnosed in women aged were included. The data were available for 9259 screen-detected breast cancers, 5413 interval cancers, and 6710 cancers in women not recently exposed to screening. In the early years of the program, the latter group mainly comprised women who had not yet been invited, whereas in the later years it was mainly made up of nonattenders. The group as a whole is referred to as unexposed for purposes of brevity. Follow-up was available through April 12, Pathology Data Invasive status (invasive, microinvasive, in situ), differentiation grade, vascular invasion, nodal status, tumor size, and tumor type (according to ICD-O3 morphology classification) were recorded from the pathology reports. In addition, estrogen receptor (ER) and progesterone receptor (PR) status were collected, although the majority of these data were not available until 2002 and 2004, respectively. Statistics Data were analyzed using the Stata software package. 13 Associations among the various parameters were analyzed using chi-square tests and logistic regression. 14 Trends over time were also analyzed using logistic regression. Survival analyses were performed using Cox regression, with the time of diagnosis as the entry date and breast cancerrelated death as outcome, 15 yielding relative hazards of breast cancer death and 95% confidence intervals on these. The extent to which screening effects on survival could be attributable to other factors was calculated by comparison of adjusted and unadjusted Cox regression analyses using the method of Freedman et al. 16 Cumulative survival was calculated using Kaplan-Meier survival curves. 15 P.05 was considered statistically significant. RESULTS Tumor Attributes and Mode of Detection A total of 21,382 breast cancers diagnosed in women aged years were studied: 43.3% were screen-detected, 25.3% were interval cancers, and 31.4% occurred in women unexposed to screening. Between the 3 groups, there were substantial differences in tumor attributes (Table 1). Screen-detected breast cancers were lower grade (better differentiated), less likely to be node-positive, more likely to be ER- or PR positive, and smaller than tumors in the 2 symptomatic groups (P <.001 in all cases). The women unexposed to screening were more likely to have larger tumors than those with interval cancers and were more likely to have nodal status, histological grade, and undetermined ER and PR status. More in situ carcinomas were present in the screen-detected group (15.5% vs 3.6% and 3.2%, respectively, P <.001). The histological type of tumors differed significantly (P < Cancer April 1,
3 Table 1. Frequencies of Pathological Attributes for Women Aged Years With Screen- Detected Tumors, Interval Tumors, and Tumors Occurring in Women Unexposed to Screening Factor % Screen- Detected n59259 % Interval n55413 % Unexposed n56710 Invasive status <.001 Invasive Microinvasive In situ Differentiation grade a <.001 Grade Grade Grade Unknown Nodal status a <.001 Negative Positive Unknown Tumor size a < mm >5 to 10 mm >10 to 15 mm >15 to 20 mm >20 to 50 mm >50 mm Tumor type a <.001 IDC ILC IDC and ILC Tubular Cribriform Medullary Mucinous SRCC Neuroendocrine Papillary Micropapillary Apocrine Metaplastic Rare types Paget Sarcoma Phylloides Not known ER status a <.001 Negative Positive Unknown PR status a <.001 Negative Positive Unknown IDC indicates invasive ductal carcinoma; ILC, invasive lobular carcinoma; SSRC, signet ring cell carcinoma; ER, estrogen receptor; PR, progesterone receptor. a Invasive tumors only. P 1362 Cancer April 1, 2011
4 Breast Cancer Differences/Nagtegaal et al Table 2. Pathological Features of In Situ Carcinomas by Detection Mode Factor % Screen- Detected n5989 % Interval n5113 % Unexposed n597 Tumor size a < mm >5 to 10 mm >10 to 15 mm >15 to 20 mm >20 to 50 mm >50 mm Tumor type <.001 DCIS LCIS DCIS and LCIS Intraductal papillary Cytonuclear grade.6 Low Intermediate High DCIS indicates ductal carcinoma in situ; LCIS, lobular carcinoma in situ. a 43% missing data. P Table 3. Annual Percentage Changes in Odds From Logistic Regression Modeling of Invasive Tumors Over the Entire Study Period ( ) Tumor Characteristics Overall Invasive tumors 6% a 10% a 5% a Node-positive b 3% a 7% a 0.8% Grade 3 cancer 4% a 10% a þ1% Size 10 mm þ2% a þ3% þ1% Size >50 mm 3% a 7% a þ4% Lobular carcinoma þ3% a þ4% a % Tubular carcinoma þ2% a þ8% a 4% a a Trend significant with p <.05. b Only patients with known nodal status were considered. Figure 1. Proportion of all breast tumors (in situ and invasive) diagnosed over time for women screened and women not screened is shown..001) by detection mode. Most tumors were invasive ductal carcinoma without further specification. In the screendetected group, there was a higher proportion of tubular carcinoma (8.4% vs 2.0% and 2.1% respectively) and a lower proportion of ductal carcinoma. Rare tumor types included acinar cell carcinoma (n ¼ 2), clear cell adenocarcinoma (n ¼ 4), and inflammatory carcinoma (n ¼ 15). Inflammatory carcinoma was mostly diagnosed symptomatically (n ¼ 1, n ¼ 9, and n ¼ 5 for screendetected cancers, interval cancers, and cancers in women unexposed to screening, respectively). The sarcomas consisted of fibrosarcomas (n ¼ 2), leiomyosarcomas (n ¼ 1), osteosarcomas (n ¼ 1), and sarcomas not otherwise specified (n.o.s.) (n ¼ 5). The in situ carcinomas that were screen-detected were smaller (Table 2) and more often ductal carcinoma in situ. Although there was a trend towards a higher cytonuclear grade for all modes of detection there was no significant difference between detection modes (P ¼.6). In situ interval cancers had the largest proportion of intraductal papillary tumors. Trends Over Time Changes in detection mode with time are shown in Figure 1. In 1988, 5.9% of all breast cancers were diagnosed in women exposed to screening (screen-detected or interval Cancer April 1,
5 Figure 2. Mode of detection data are shown for (A) node positivity in invasive breast tumors, (B) grade 3 invasive breast tumors, (C) lobular invasive breast tumors, (D) invasive breast tumors 10 mm, (E) tubular invasive breast tumors, and (F) invasive breast tumors >50 mm. cancers), whereas in 1997, 78.1% of all breast cancers were diagnosed in women who had been exposed to screening. This figure rose slightly each year and was 81.9% for all breast cancers in This was contemporaneous with considerable changes in the distribution of pathological features in invasive cancers (Table 3). We determined the trends in time during the starting phase of the program ( ) and during the continuation 1364 Cancer April 1, 2011
6 Breast Cancer Differences/Nagtegaal et al Figure 3. Kaplan-Meier survival curve for women aged years diagnosed with invasive breast tumors is shown. phase ( ) using logistic regression with year as a continuous variable. Overall, there were reductions with time in the proportion of invasive breast cancers, node-positive cancers, grade 3 cancers, and large (pt3) invasive tumors >50 mm; these were much more pronounced during the starting phase of the program. Overall and during the early years there was a 2% and 8% annual increase, respectively, in the proportion of tubular carcinomas, whereas during the later years there was a 4% annual decrease. When evaluating trends in time for the different detection modes (screen-detected, interval, women unexposed to screening; Figure 2), changes in interval cancers and cancers in women unexposed to screening were remarkably similar for node positivity, poor differentiation, and small tumors (<10 mm). For screen-detected cancers, node positivity and poor differentiation were always significantly lower and small tumors were always significantly higher than for the other two detection modes. Large tumors (pt3) with diameter >50 mm were consistently more often present in the unexposed group compared with both interval and screen-detected cancers. Tubular carcinoma was consistently higher in the screen-detected group, but with time an increase in lobular carcinoma was present in all 3 groups. Within the detection modes, proportions of small tumors and tubular carcinomas remained constant, indicating that the overall increases were due to the increase in the proportion of screen-detected tumors. Survival Women with screen-detected cancers had a better prognosis than women with interval cancers and cancers in women with no screening (Figure 3). Ten-year survival rates for invasive breast cancer were 85.5%, 69.8%, and 57.7%, respectively (P <.001), with an overall rate of 71.6%. These differences are also reflected in the unadjusted Cox regression model (Table 4) for invasive breast tumors only, in which the hazard ratios for interval cancers and cancers in women unexposed to screening were 2.3 and 3.4, respectively, for breast cancer-related death. In the adjusted model, after correction for nodal status, tumor size, differentiation grade, tumor type, age, and year of diagnosis, this difference was smaller but was still present, with hazard ratios of 1.26 and 1.54, respectively. When adjusted for age, tumor size, and node status only, the hazard ratios for interval cancers and cancers in women who had not been screened were 1.56 and 2.04, respectively, compared with screen-detected cancers (complete results are available from the authors). The Freedman statistics for the proportion of the survival differences for invasive cancers explained by age, tumor size, and node status were 47% for the difference in survival between screen-detected and interval cancers and 42% for the difference between screen-detected cancers and cancers in women unexposed to screening. Additional adjustment for grade, tumor type, and year of diagnosis accounted for a further 17% and 26%, respectively, bringing the total proportions explained to 64% and 68%, respectively. When evaluating screening status and year of diagnosis only, the Freedman proportions explained for interval cancers and cancers in women unexposed to screening were 0.03% and 4.8%, respectively, suggesting that the better prognosis of screen-detected cancers was not simply due to the strong confounding with year of diagnosis. On the other hand, for year of diagnosis, the Freedman statistic for the proportion of the year of diagnosis effect explained by confounding with detection mode was 34%, which means that a substantial part of the increase in survival by year of diagnosis is explained by the increase in the proportion of screen-detected cancers. This finding is consistent with the predicted 10-year survival rates from the Cox regression model, including year of diagnosis and detection mode in 1990 and 1997, respectively (Table 5). Expected survival rates increased during these 7 years for all detection modes, but most of the change in overall survival was due to the increased proportion of screendetected cases (a 2% increase) and the improved survival of the symptomatic cancers (a 3% increase). Ten-year survival for women with screen-detected cancers and women unexposed to screening increased over time, but the survival of women with interval cancers decreased by 1.5%. Cancer April 1,
7 Table 4. Unadjusted and Adjusted Cox Regression Model for Breast Cancer Survival After Invasive Carcinoma Factor Unadjusted HR n519,411 Adjusted HR n510,245 HR 95% CI P HR 95% CI P Histological type <.001 Screen-detected Interval < Unexposed < Nodal status <.001 Negative Positive < Unknown < Tumor size < mm >5 to 10 mm >10 to 15 mm >15 to 20 mm < >20 to 50 mm < >50 mm < Differentiation grade <.001 Grade Grade < Grade < Age, y < < Tumor type Ductal carcinoma Lobular carcinoma < Tubular carcinoma < Other carcinoma < Other malignancy Vascular invasion a <.001 No Yes < Year of diagnosis < <.001 HR indicates hazard ratio; CI, confidence interval. a 43.4% missing data. DISCUSSION In this study, of more than 21,000 breast cancers diagnosed in women aged years since the initiation of breast screening in the West Midlands, we found more favorable tumor size, nodal status, grade, and hormone receptor status in screen-detected breast cancers than in symptomatic cancers, as one might expect from the results of other studies Of the screen-detected invasive cancers, 30% were 10 mm compared with 11% of interval cancers and 9.8% of cancers in women unexposed to screening. Also, as expected, 17,22 there was a higher proportion of in situ tumors among screen-detected cancers. Screen-detected invasive tumors had a higher proportion of tubular cancers (8.4% vs 2% in the symptomatic tumors), and a lower proportion of ductal cancers (76.0% vs 78.6% and 79.8%). Interval cancers contained a higher proportion of lobular cancers. Screen-detected in situ cancers had a significantly higher proportion of ductal carcinoma in situ. The proportion of screen-detected tumors, including both in situ and invasive, rose from 5.9% in 1988 to 43.5% in 1996 and 55.0% in The proportion of tumors in women exposed to screening (screen-detected plus interval cancers) rose from 5.9% in 1988 to 76.1% in 1366 Cancer April 1, 2011
8 Breast Cancer Differences/Nagtegaal et al Table 5. Predicted Survival by Detection Mode and Year of Diagnosis (Invasive Tumors Only) Detection Mode Percentage of Cases Year Survival Percentage of Cases 10-Year Survival Percentage of Cases 10-Year Survival Screen-detected Interval Unexposed to screening Total All data are expressed as percentages (%) and were derived using Cox regression and 81.9% in During the start-up phase of the screening program ( ), dramatic reductions were observed in invasive tumors in the proportions of node-positive, grade 3 and large (>50 mm) tumors, along with substantial increases in small (10 mm) tumors, tubular carcinomas, and lobular carcinomas. In the continuation phase, after 1996, these trends were either absent, reversed, or much attenuated. Further investigation of the trends showed that the changes in the proportions of tubular and small tumors were largely due to the increase in the proportion of screen-detected cancers. Within both the screen-detected and the symptomatic tumors, the proportion of small tumors remained roughly constant over time, but the proportion of tubular cancers declined in the continuation phase. The slow development of tubular carcinoma implies a long lead time and suggests that many of the asymptomatic tubular cancers were diagnosed during the early years of the program, when most of the screening episodes were prevalent screens. Screen-detected invasive breast cancers had substantially better survival than either interval cancers or cancers in women unexposed to screening, which is consistent with the findings of others. 11,12,18,19 Of this survival advantage, approximately 64%-68% could be explained by age, tumor size, nodal status, grade, tumor type, and year of diagnosis, whereas 42%-47% could be explained by age, tumor size, and nodal status only. Because only a small minority of cases had ER and PR data, we were unable to assess the impact of these confounding factors. These results suggest that the majority of the difference in prognosis of screen-detected cancers can be attributed to age and histological characteristics. The remaining 32%-36% of the survival difference between screendetected and symptomatic tumors may be partly due to effects of early detection, for which we have no data (eg, the number of nodes involved in node-positive tumors), partly due to lead time and partly due to length bias, which might be manifested by differences in biological features such as HER2/neu status and epithelial proliferation rate. Certainly, there were more ER- and PR-positive cases among the screen-detected tumors in the years for which these data were available. When considering possible biological differences between screen-detected and symptomatic breast cancers, it should be noted that any such difference is quantitative rather than qualitative. Screening does not exclusively single out ER-positive or well-differentiated tumors; rather, higher percentages of such tumors are represented in a screen-detected tumor series. It is also worth noting that there is evidence that histological grade may change as a tumor develops 23 (although these findings have been contested by some 24 ), so that a difference in grade between screen-detected and symptomatic invasive breast cancer may be an effect of early detection rather than length bias. This may also be the case for hormone receptor status. Ongoing studies are evaluating how much of the screening effect can be attributed to lead time and length bias. In the meantime, it is clear that the screening program in the West Midlands has brought about substantial changes in tumor attributes and improvements in survival, mainly due to a higher proportion of screendetected cases rather than to changes in prognosis within screen-detected cases. The better survival for women with screen-detected cancers explains much of the improved survival by year of diagnosis, rather than vice versa. Most of this survival can be accounted for by age and the routinely measured histological factors of tumor size, nodal status, grade, and tumor type, leaving approximately onequarter of the effect to be explained by lead time and unmeasured biological features. CONFLICT OF INTEREST DISCLOSURES Supported by Cancer Research UK and the Breast Cancer Research Trust. Iris Nagtegaal was supported by a fellowship from the Dutch Cancer Society. Cancer April 1,
9 REFERENCES 1. Swedish Organised Service Screening Evaluation Group. Reduction in breast cancer mortality from organised service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev. 2006;15: Swedish Organised Service Screening Evaluation Group. Reduction in breast cancer mortality from organised service screening with mammography: 2. Validation with alternative analytic methods. Cancer Epidemiol Biomarkers Prev. 2006; 15: Paci E, Duffy SW, Giorgi D, et al. Are breast cancer screening programmes increasing rates of mastectomy? Observational study. Br Med J. 2002;325: Olsen AH, Agbaje OF, Myles JP, Lynge E, Duffy SW. Overdiagnosis, sojourn time and sensitivity in the Copenhagen Mammography Screening Programme. Breast J. 2006;12: Alexander FE, Anderson TJ, Hubbard AL. Screening status in relation to biological and chronological characteristics of breast cancers: a cross-sectional survey. J Med Screen. 1997;4: Gilliland FD, Joste N, Stauber PM, et al. Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst. 2000;92: Smith RA, Duffy SW, Gabe R, Tabar L, Yen AMF, Chen HHT. The randomized trials of breast cancer screening: what have we learned? Radiol Clin North Am. 2004;42: Anderson TJ, Lamb J, Donnan P, et al. Comparative pathology of breast cancer in a randomised trial of screening. Br J Cancer. 1991;64: Porter PL, El-Bastawissi AY, Mandelson MT, et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 1999;91: Webster LR, Bilous AM, Willis L, et al. Histopathologic indicators of breast cancer biology: insights from population mammographic screening. Br J Cancer. 2005;92: Duffy SW, Tabar L, Fagerberg G, et al. Breast screening, prognostic factors and survival results from the Swedish two-county study. Br J Cancer. 1991;64: Lawrence G, O Sullivan E, Kearins O, Tappenden N, Martin K, Wallis M. Screening histories of invasive breast cancers diagnosed in the West Midlands, UK: variation with time and impact on 10 year survival. J Med Screen. 2009;16: StataCorp. Stata release 9: user s guide. College Station, TX: Stata Press; Breslow NE, Day NE. Statistical methods in cancer research. volume 1: the analysis of case-control studies. Lyon, France: IARC; Collett, D. Modelling survival data in medical research. New York, NY: Chapman and Hall; Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med. 1992;11: Lindgren A, Holmberg L, Thurfjell E. The influence of mammography screening on the pathological panorama of breast cancer. APMIS 1997;105: Ernst MF, Roukema JA, Coebergh JWW, et al. Breast cancers found by screening: earlier detection, lower malignant potential or both? Breast Cancer Res Treat. 2002;76: Jensen AR, Garne JP, Storm HH, et al. Stage and survival in breast cancer patients in screened and non-screened Danish and Swedish populations. Acta Oncol. 2003;42: Thomson CS, Brewster DH, Dewar JA, Twelves CJ. Improvements in survival for women with breast cancer in Scotland between 1987 and 1993: impact of earlier diagnosis and changes in treatment. Eur J Cancer. 2004;40: Shen Y, Yang Y, Inoue LYT, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomised screening trials. J Natl Cancer Inst. 2005;97: Ng EH, Ng FC, Tan PH, et al. Results of intermediate measures from a population-based, randomized trial of mammographic screening prevalence and detection of breast carcinoma among Asian women. Cancer. 1998;82: Anderson TJ, Waller M, Ellis IO, Bobrow L, Moss S. Influence of annual mammography from age 40 on breast cancer pathology. Hum Pathol. 2004;35: Johnson A, Shekhdar J. Does breast cancer grade worsen with time? Evidence from breast screening. Breast Cancer Res Treat. 2001;68: Cancer April 1, 2011
Life Expectancy of Screen-Detected Invasive Breast Cancer Patients Compared With Women Invited to the Nijmegen Screening Program
Original Article Life Expectancy of Screen-Detected Invasive Breast Cancer Patients Compared With Women Invited to the Nijmegen Screening Program Johannes D. M. Otten 1,2 ; Mireille J. M. Broeders 1,2,3
More informationStephen W Duffy, Laszlo Tabar, Anne Helene Olsen, Bedrich Vitak, Prue C Allgood, Tony H H Chen, Amy M F Yen and Robert A Smith...
25 ORIGINAL ARTICLE Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England Stephen W Duffy, Laszlo Tabar,
More informationCarcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS
Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific
More informationQuantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme
British Journal of Cancer (2002) 87, 65 69 All rights reserved 0007 0920/02 $25.00 www.bjcancer.com Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme
More informationContents 1 The Windows of Susceptibility to Breast Cancer 2 The So Called Pre-Neoplastic Lesions and Carcinoma In Situ
Contents 1 The Windows of Susceptibility to Breast Cancer... 1 1.1 Introduction... 1 1.2 Risk Factor and Etiological Agents... 2 1.3 The Concept of the Windows of Susceptibility to Carcinogenesis... 5
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationRare Breast Tumours. 1. Breast Tumours. 1.1 General Results. 1.2 Incidence
Rare Breast Tumours 1. Breast Tumours 1.1 General Results Table 1. Epithelial Tumours of Breast: Incidence, Trends, Survival Flemish Region 2001-2010 Incidence Trend Survival Females EAPC Relative survival
More informationBreast Screening: risks if you do and risks if you don t. Stephen W. Duffy Wolfson Institute of Preventive Medicine
Breast Screening: risks if you do and risks if you don t Stephen W. Duffy Wolfson Institute of Preventive Medicine General principle There is often discussion of benefits and harms of breast screening
More informationScreen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study
Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study Stephen W Duffy, Amanda Dibden, Dimitrios Michalopoulos,
More informationAssociation of symptoms and interval breast cancers in the mammography-screening programme: population-based matched cohort study
www.nature.com/bjc ARTICLE Epidemiology Association of symptoms and interval breast cancers in the mammography-screening programme: population-based matched cohort study Deependra Singh 1,, Joonas Miettinen
More informationInterval cancers in BreastScreen Aotearoa
in BreastScreen Aotearoa 1999 2007 Richard Taylor Madeleine Wall Stephen Morrell Independent Monitoring Group School of Public Health and Community Medicine University of New South Wales for BreastScreen
More informationHistological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological Type
More informationAre Small Breast Cancers Good because They Are Small or Small because They Are Good?
The new england journal of medicine Special Report Are Small Breast Cancers Good because They Are Small or Small because They Are Good? Donald R. Lannin, M.D., and Shiyi Wang, M.D., Ph.D. The recent article
More informationBasal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up ...
21 ORIGINAL ARTICLE Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up A J Evans, E A Rakha, S E Pinder, A R Green, C Paish and I O Ellis...
More informationInterval Cancers in BreastScreen Aotearoa
Interval Cancers in BreastScreen Aotearoa 2008 2009 Released 2018 nsu.govt.nz Citation: National Screening Unit. 2018. Interval Cancers in BreastScreen Aotearoa 2008 2009. Wellington: Ministry of Health.
More informationLandmarking, immortal time bias and. Dynamic prediction
Landmarking and immortal time bias Landmarking and dynamic prediction Discussion Landmarking, immortal time bias and dynamic prediction Department of Medical Statistics and Bioinformatics Leiden University
More informationHormone receptor and Her2 neu (Her2) analysis
ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting
More informationMammographic Tumor Features Can Predict Long- Term Outcomes Reliably in Women with 1 14-mm Invasive Breast Carcinoma
1745 Mammographic Tumor Features Can Predict Long- Term Outcomes Reliably in Women with 1 14-mm Invasive Breast Carcinoma Suggestions for the Reconsideration of Current Therapeutic Practice and the TNM
More informationMorphological and Molecular Typing of breast Cancer
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological
More informationAudit. Public Health Monitoring Report on 2006 Data. National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons.
National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons Audit Public Health Monitoring Report on 2006 Data November 2009 Prepared by: Australian Safety & Efficacy Register of
More informationBreast pathology. 2nd Department of Pathology Semmelweis University
Breast pathology 2nd Department of Pathology Semmelweis University Breast pathology - Summary - Benign lesions - Acute mastitis - Plasma cell mastitis / duct ectasia - Fat necrosis - Fibrocystic change/
More informationSurgical Pathology Issues of Practical Importance
Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast
More informationModelling the overdiagnosis of breast cancer due to mammography screening in women aged 40 to 49 in the United Kingdom
RESEARCH ARTICLE Open Access Modelling the overdiagnosis of breast cancer due to mammography screening in women aged 40 to 49 in the United Kingdom Necdet B Gunsoy 1*, Montserrat Garcia-Closas 1,2 and
More informationEffect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
Effect of and in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ trial Jack Cuzick, Ivana Sestak, Sarah E Pinder, Ian O Ellis, Sharon Forsyth, Nigel J Bundred, John
More informationMy Personalized Breast Cancer Worksheet
My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationLaboratory for Quantitative Medicine Technical Report #2 April 10, Equation Parameters
Laboratory for Quantitative Medicine Technical Report #2 April 10, 2009 Equation Parameters This report summarizes all the equation parameters used by the web-based calculators, and provides information
More informationBMaP-3 Cancer Database. Aggregate Data File
BMaP-3 Cancer Database Aggregate Data File Contents BMaP-3 Cancer Database... 1 Aggregate Data File... 1 Frequency Tables... 2 Institution... 2 Year_First_Contact... 2 Primary_Site... 3 Sex... 3 Race...
More informationCite this article as: BMJ, doi: /bmj (published 13 January 2005)
Cite this article as: BMJ, doi:10.1136/bmj.38313.639236.82 (published 13 January 2005) in Copenhagen after introduction of mammography screening: cohort study Anne Helene Olsen, Sisse H Njor, Ilse Vejborg,
More informationMammographic density and risk of breast cancer by tumor characteristics: a casecontrol
Krishnan et al. BMC Cancer (2017) 17:859 DOI 10.1186/s12885-017-3871-7 RESEARCH ARTICLE Mammographic density and risk of breast cancer by tumor characteristics: a casecontrol study Open Access Kavitha
More informationRecent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
More informationChapter 13 Cancer of the Female Breast
Lynn A. Gloeckler Ries and Milton P. Eisner INTRODUCTION This study presents survival analyses for female breast cancer based on 302,763 adult cases from the Surveillance, Epidemiology, and End Results
More informationACRIN 6666 Therapeutic Surgery Form
S1 ACRIN 6666 Therapeutic Surgery Form 6666 Instructions: Complete a separate S1 form for each separate area of each breast excised with the intent to treat a cancer (e.g. each lumpectomy or mastectomy).
More informationΟutcomes for patients who are diagnosed with breast and endometrial cancer
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2013 Οutcomes for patients who are diagnosed with breast and endometrial cancer Tonya M. Martin-Dunlap Washington
More informationLife expectancy in the United States continues to lengthen.
Reduced Mammographic Screening May Explain Declines in Breast Carcinoma in Older Women Robert M. Kaplan, PhD and Sidney L. Saltzstein, MD, MPH wz OBJECTIVES: To examine whether declines in breast cancer
More informationLOBULAR CARCINOMA IN SITU: WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE
: WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University of Washington Joint Member, Fred Hutchinson Cancer
More informationPapillary Lesions of the Breast: WHO Update
Papillary Lesions of the Breast: WHO Update Stuart J. Schnitt, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA, USA Papillary Lesions of the Breast
More informationMultiparameter characterization of breast carcinoma: subgross, microscopy, proteins, and genes
World Congress on Breast Cancer August 1-3, 2015, Birmingham, UK Multiparameter characterization of breast carcinoma: subgross, microscopy, proteins, and genes Tibor Tot Falun, Sweden Lake Varpan, Falun,
More informationProperties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.12.4921 Properties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up RESEARCH ARTICLE Properties of Synchronous Versus Metachronous
More informationIntroduction. Wilfred Truin 1 Rudi M. H. Roumen. Vivianne C. G. Tjan-Heijnen 2 Adri C. Voogd
Breast Cancer Res Treat (2017) 164:133 138 DOI 10.1007/s10549-017-4220-x EPIDEMIOLOGY Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients
More informationTable of contents. Page 2 of 40
Page 1 of 40 Table of contents Introduction... 4 1. Background Information... 6 1a: Referral source for the New Zealand episodes... 6 1b. Invasive and DCIS episodes by referral source... 7 1d. Age of the
More informationBreastScreen Aotearoa Annual Report 2015
BreastScreen Aotearoa Annual Report 2015 EARLY AND LOCALLY ADVANCED BREAST CANCER PATIENTS DIAGNOSED IN NEW ZEALAND IN 2015 Prepared for Ministry of Health, New Zealand Version 1.0 Date November 2017 Prepared
More informationRare types of breast carcinoma
Open Med. 2015; 10: 92-96 Research Article Open Access Daiva Gudaviciene*, Laura Steponaviciene, Raimundas Meskauskas, Giedre Smailyte, Eduardas Aleknavicius Rare types of breast Abstract: Breast cancer
More informationBREAST CANCER SCREENING:
BREAST CANCER SCREENING: controversies D David Dershaw Memorial Sloan Kettering Cancer Center New York, NY Areas of general agreement about mammographic screening Screening mammography has been demonstrated
More informationRESEARCH. Breast cancer mortality in organised mammography screening in Denmark: comparative study
1 The Nordic Cochrane Centre, Rigshospitalet, University of Copenhagen, Denmark 2 Norwegian Institute of Public Health, Oslo, Norway Correspondence to: K J Jørgensen kj@cochrane.dk Cite this as: BMJ 2010;340:c1241
More informationSummary of the BreastScreen Aotearoa Mortality Evaluation
Summary of the BreastScreen Aotearoa Mortality Evaluation 1999 2011 Released 2015 nsu.govt.nz Citation: Ministry of Health. 2015. Summary of the BreastScreen Aotearoa Mortality Evaluation 1999 2011. Wellington:
More informationComparative pathology of breast cancer in a randomised trial of screening
Br. J. Cancer (1991), 64, 18-113 '." Macmillan Press Ltd., 1991 Br. J. Cancer (1991), 64, 18 113 Comparative pathology of breast cancer in a randomised trial of screening T.J. Anderson', J. Lamb', P. Donnan2,
More informationBone Sarcoma Incidence and Survival. Tumours Diagnosed Between 1985 and Report Number R12/05
Bone Sarcoma Incidence and Survival Tumours Diagnosed Between 1985 and 29 Report Number R12/5 October 212 For any enquiries regarding the information in this report please contact: Mr Matthew Francis West
More informationAnnual Screening Mammography for Breast Cancer in Women 75 Years Old or Older: To Screen or Not to Screen
Women s Imaging Original Research Hartman et al. Annual Screening Mammography of Women 75 Years Old or Older Women s Imaging Original Research Maya Hartman 1 Michele Drotman Elizabeth Kagan Arleo Hartman
More informationCLINICAL SIGNIFICANCE OF BENIGN EPITHELIAL CHANGES
Papillomas. Papillomas are composed of multiple branching fibrovascular cores, each having a connective tissue axis lined by luminal and myoepithelial cells ( Fig. 23-11 ). Growth occurs within a dilated
More informationProtocol for the Examination of Biopsy Specimens From Patients With Invasive Carcinoma of the Breast
Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast Version: BreastInvasive 1.0.0.0 Protocol Posting Date: February 2019 Accreditation Requirements The use of
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationFISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC
Classification of Breast Cancer in the Molecular Era Susan J. Done University Health Network, Toronto Why classify? Prognosis Prediction of response to therapy Pathogenesis Invasive breast cancer can have
More informationBreast Cancer 100: Overview of Breast Cancer in Native Americans
Breast Cancer 100: Overview of Breast Cancer in Native Americans Native American Cancer Research A Native operated non-profit corporation 3022 South Nova Road Pine, CO 80470-7830 Phone: 303-838-9359 Fax:
More informationPrognostic factors in women with breast cancer: distribution by socioeconomic status and evect on diverences in survival
308 Scottish Cancer Intelligence Unit, Information and Statistics Division, Trinity Park House, Edinburgh EH5 3SQ, UK C S Thomson D H Brewster R J Black West of Scotland Cancer Surveillance Unit, Department
More informationTrends in Breast Cancer Mortality in Sweden before and after Implementation of Mammography Screening
Trends in Breast Cancer Mortality in Sweden before and after Implementation of Mammography Screening Jari Haukka 1 *, Graham Byrnes 2, Mathieu Boniol 2, Philippe Autier 2 1 Faculty of Medicine, Department
More informationEvaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients
BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan
More informationCurrent Status of Supplementary Screening With Breast Ultrasound
Current Status of Supplementary Screening With Breast Ultrasound Stephen A. Feig, M.D., FACR Fong and Jean Tsai Professor of Women s Imaging Department of Radiologic Sciences University of California,
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationBREAST PATHOLOGY. Fibrocystic Changes
BREAST PATHOLOGY Lesions of the breast are very common, and they present as palpable, sometimes painful, nodules or masses. Most of these lesions are benign. Breast cancer is the 2 nd most common cause
More informationXXV Congreso de la Sociedad Española de Anatomía Patológica y División Española de la International Academy of Pathology
XXV Congreso de la Sociedad Española de Anatomía Patológica y División Española de la International Academy of Pathology NUEVOS FENOTIPOS DEL CÁNCER DE MAMA: NUEVOS PROBLEMAS PARA EL PATÓLOGO? Tienen actualmente
More informationSupplementary Online Content
Supplementary Online Content Giannakeas V, Sopik V, Narod SA. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy. JAMA Netw Open. 2018;1(4):e181100.
More informationMale Breast Cancer in the Veterans Affairs Population
1471 Male Breast Cancer in the Veterans Affairs Population A Comparative Analysis Zeina A. Nahleh, MD 1,2 Roopa Srikantiah, MD 1,2 Malek Safa, MD 1,2 Abdul-Rahman Jazieh, MD 1 Albert Muhleman, MD 1,2 Rami
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationChildhood Cancer Survivor Study Analysis Concept Proposal
Title: Multiple Subsequent Neoplasms Working Group and Investigators: Childhood Cancer Survivor Study Analysis Concept Proposal This proposed publication will be within the Second Malignancy Working Group
More informationFlat Epithelial Atypia
Flat Epithelial Atypia Richard Owings, M.D. University of Arkansas for Medical Sciences Department of Pathology Flat epithelial atypia can be a difficult lesion May be a subtle diagnosis Lots of changes
More informationEstimating mean sojourn time and screening sensitivity using questionnaire data on time since previous screening
Estimating mean sojourn time and screening sensitivity using questionnaire data on time since previous screening Harald Weedon-Fekjær, Bo H. Lindqvist, Odd O. Aalen, Lars J. Vatten and Steinar Tretli Short
More informationGeneral principles of screening: A radiological perspective
General principles of screening: A radiological perspective Fergus Coakley MD, Professor and Chair, Diagnostic Radiology, Oregon Health and Science University General principles of screening: A radiological
More informationDiseases of the breast (2 of 2) Breast cancer
Diseases of the breast (2 of 2) Breast cancer Epidemiology & etiology The most common type of cancer & the 2 nd most common cause of cancer death in women 1 of 8 women in USA Affects 7% of women Peak at
More informationDisclosure of Relevant Financial Relationships. Breast Pathology Evening Specialty Conference Case #4. Clinical Case: Pathologic Features
Breast Pathology Evening Specialty Conference Case #4 K.P. Siziopikou, MD, PhD Professor of Pathology Director of Breast Pathology and Breast Pathology Fellowship Program Northwestern University Feinberg
More informationUse of a Protease Activated System for Real-time Breast Cancer Lumpectomy Margin Assessment
Use of a Protease Activated System for Real-time Breast Cancer Lumpectomy Margin Assessment Barbara L. Smith, MD, PhD Professor of Surgery, Harvard Medical School Division of Surgical Oncology Massachusetts
More informationCohort and Case Control Analyses of Breast Cancer Mortality: BreastScreen Aotearoa
Cohort and Case Control Analyses of Breast Cancer Mortality: BreastScreen Aotearoa 1999-2011 by Stephen Morrell, 1 Richard Taylor, 1 David Roder, 2 Bridget Robson 3 1. School of Public Health and Community
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationInterpretation of Breast Pathology in the Era of Minimally Invasive Procedures
Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine Jacksonville Medical Director, UF Health Breast Center Chief of Pathology
More informationShort Term Cancer Risk
in a Cohort of 2312 Women with High Risk Breast Lesions Kubat E 1, Puligandla B 2, Collins L 3, Jiang SF 4, Callahan M 5, Kutner S 6, Habel L 4, Shim V 1 1 Surgery, Kaiser Permanente, Oakland, CA; 2 Pathology,
More informationBreast Cancer Update 2018 The Latest in Diagnosis and Treatment SARATH K, PALAKODETI, DO, FAACS GENERAL, BREAST, AND COSMETIC SURGEON TOLEDO CLINIC
Breast Cancer Update 2018 The Latest in Diagnosis and Treatment SARATH K, PALAKODETI, DO, FAACS GENERAL, BREAST, AND COSMETIC SURGEON TOLEDO CLINIC Objectives Identify breast lesions and masses, and know
More informationBreast Cancer Characteristics Associated With Digital Versus Film-Screen Mammography for Screen-Detected and Interval Cancers
Women s Imaging Original Research Henderson et al. Digital Versus Film-Screen Mammography Women s Imaging Original Research Louise M. Henderson 1 Diana L. Miglioretti 2 Karla Kerlikowske 3 Karen J. Wernli
More informationPaget's Disease of the Breast: Clinical Analysis of 45 Patients
236 Paget's Disease of the Breast: Clinical Analysis of 45 Patients Mingfian Yang Hao Long Jiehua He Xi Wang Zeming Xie Department of Thoracic Oncology, Cancer Center of Sun Yat-sen University, Guangzhou
More informationLesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node
Lesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node Oil Cyst Mass, Intermediate Concern Microlobulated Margins Obscured Margins Mass, Favoring Malignant Indistinct
More informationDOCTORAL THESIS SUMMARY
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA FACULTY OF MEDICINE DOCTORAL THESIS SUMMARY CLINICO-IMAGING STUDY OF INVASIVE DUCTAL BREAST CARCINOMAS CORRELATED TO HORMONAL RECEPTORS AND HER2/NEU ONCOPROTEIN
More informationOverdiagnosis of Breast Cancer: Myths and Facts
Overdiagnosis of Breast Cancer: Myths and Facts Mark A. Helvie, MD Department of Radiology Comprehensive Cancer Center University of Michigan Health System April 7, 2016 Objectives Define overdiagnosis
More informationInvasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database
Wang et al. BMC Cancer 2014, 14:147 RESEARCH ARTICLE Open Access Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database
More informationProliferative Breast Disease: implications of core biopsy diagnosis. Proliferative Breast Disease
Proliferative Breast Disease: implications of core biopsy diagnosis Jean F. Simpson, M.D. Breast Pathology Consultants, Inc. Nashville, TN Proliferative Breast Disease Must be interpreted in clinical and
More informationOne Breast Cancer Annual Report
One 2015 Breast Cancer Annual Report One OVERVIEW The Breast Program at Carolinas HealthCare System s Levine Cancer Institute, offers comprehensive care. Patients with benign and malignant disease of the
More informationColumnar Cell Lesions
Columnar Cell Lesions Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Question? Columnar cell lesions are: a) Annoying lesions
More informationA712(18)- Test slide, Breast cancer tissues with corresponding normal tissues
A712(18)- Test slide, Breast cancer tissues with corresponding normal tissues (formalin fixed) For research use only Specifications: No. of cases: 12 Tissue type: Breast cancer tissues with corresponding
More informationMultiple Primary and Histology Site Specific Coding Rules BREAST. FLORIDA CANCER DATA SYSTEM MPH Breast Site Specific Coding Rules
Multiple Primary and Histology Site Specific Coding Rules BREAST 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways to view the Multiple l Primary/Histology
More informationBreast Pathology. Breast Development
Breast Pathology Lecturer: Hanina Hibshoosh, M.D. Reading: Kumar, Cotran, Robbins, Basic Pathology, 6th Edition, pages 623-635 Breast Development 5th week - thickening of the epidermis - milk line 5th
More informationAuthors: Thais Abreu de ALMEIDA 1, Institution:
Correlation of CYP2D6 s genotype and phenotype with clinicopathological characterization and impact on survival in Brazilian breast cancer population: a prospective study. Authors: Thais Abreu de ALMEIDA
More informationFINALIZED SEER SINQ QUESTIONS
0076 Source 1: WHO Class CNS Tumors pgs: 33 MP/H Rules/Histology--Brain and CNS: What is the histology code for a tumor originating in the cerebellum and extending into the fourth ventricle described as
More informationTumor Growth Rate (TGR) A New Indicator of Antitumor Activity in NETS? IPSEN NET Masterclass Athens, 12 th November 2016
1 Tumor Growth Rate (TGR) A New Indicator of Antitumor Activity in NETS? IPSEN NET Masterclass Athens, 12 th November 2016 Philippe RUSZNIEWSKI ENETS Centre of Excellence, Beaujon Hospital, Clichy, France
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationUptake of breast cancer screening in older women
Age and Ageing 2000; 29: 131 135 Uptake of breast cancer screening in older women NIA I. EDWARDS, DEE A. JONES 1 University Department of Geriatric Medicine, Glan Clwyd Hospital, Rhyl, Denbighshire, North
More informationBreastScreen Victoria Annual Statistical Report
BreastScreen Victoria Annual Statistical Report 29 BREASTSCREEN VICTORIA: ANNUAL STATISTICAL REPORT, 29 Produced by: BreastScreen Victoria Coordination Unit Level, 3 Pelham Street, Carlton South Victoria
More information6/3/2010. Outline of Talk. Lobular Breast Cancer: Definition of lobular differentiation. Common Problems in Diagnosing LCIS in Core Biopsies
Outline of Talk Lobular Breast Cancer: Common Problems in Diagnosing LCIS in Core Biopsies Definition of lobular differentiation Variants of LCIS that: carry risk for unsampled invasive cancer mimic DCIS
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast
Collecting Cancer Data Breast NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationQuantifying Breast Cancer Over-diagnosis in an Organised Mammography Screening Program
Quantifying Breast Cancer Over-diagnosis in an Organised Mammography Screening Program KERRI BECKMANN BSc (Hons) MPH September 2014 Discipline of Public Health School of Population Health Faculty of Health
More information